Direct effect of hypoglycemic sulphonylureas on the cardiovascular system of dogs
| Autor: | Zoltán Aranyi, Gábor Pogátsa, Mária-Zsófia Koltai, György Ballagi-Pordány |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Blood Glucose
Male Inotrope medicine.medical_specialty Endocrinology Diabetes and Metabolism Blood Pressure Cardiovascular System Glibenclamide Dogs Endocrinology Tolbutamide Heart Rate Reference Values Diabetes mellitus Internal medicine Internal Medicine medicine Animals Hypoglycemic Agents Gliclazide Cardiac Output Dose-Response Relationship Drug business.industry Body Weight Hemodynamics General Medicine medicine.disease Myocardial Contraction Carbutamide Sulfonylurea Compounds Blood pressure Potassium Regression Analysis Female business medicine.drug Glipizide |
| Zdroj: | Diabetes Research and Clinical Practice. 11:47-52 |
| ISSN: | 0168-8227 |
| DOI: | 10.1016/0168-8227(91)90140-9 |
| Popis: | The effects of first generation sulphonylurea compounds carbutamide, gliclazide and tolbutamide as well as second generation compounds glibenclamide and glipizide on the cardiovascular system were investigated in dogs. Six dogs received each compound intravenously at cumulative dose levels of 74, 296, 1184 mumol/kg of carbutamide and tolbutamide, 0.4, 2.0, 10.0 mumol/kg of glibenclamide and glipizide, and 16, 48 and 144 mumol/kg of gliclazide. Mean arterial blood pressure, myocardial contractile force, cardiac output and heart rate were measured. The rate of change of myocardial contractile force development (positive dF/dt), as well as of myocardial relaxation (negative dF/dt) were measured. The first generation sulphonylureas were found, in dogs, to exert a positive inotropic effect in contrast to second generation compounds. The clinical importance of our findings may be in the potential for the malfunction of the cardiovascular system (based on cardiopathy, neuropathy, atherosclerosis, and obesity), developing in diabetes, to be further impaired by the first generation sulphonylureas. Therefore, second generation sulphonylureas should be preferred in the therapy of type 2 diabetics, if satisfactory metabolic control cannot be achieved by dietary management alone and sulphonylurea treatment becomes necessary. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|